The standard regimen of omalizumab is often modified in patients with chronic spontaneous urticaria, with several factors predicting dose adjustments.

More information: Robert Wood et al, Treatment of Multi-Food Allergy with Omalizumab Compared to Omalizumab-Facilitated Multi ...

The FDA approved omalizumab-igec (Omlyclo) as the first biosimilar for omalizumab (Xolair) and the first for any respiratory ...

Last year, the US Food and Drug Administration (FDA) approved omalizumab— an injectable medication already used for allergic asthma, chronic hives, and nasal polyps — for food allergies in ...

Thirty-six percent of patients treated with omalizumab were able to tolerate 2000mg of peanut protein and 2 other food allergens without experiencing an allergic reaction compared with 19% of OIT ...

87.3% of white patients and 92.8% of Black patients had no severe exacerbations with omalizumab. 4% of white patients and 2.9% of Black patients had a serious adverse event with omalizumab.

Director of the Eudowood Division of Allergy, Immunology and Rheumatology at Johns Hopkins Children’s Center, Robert Wood, MD led a clinical trial on omalizumab — an already FDA-approved drug ...

New research, led by Johns Hopkins Children’s Center investigators and sponsored by the National Institutes of Health’s (NIH) National Institute of Allergy and Infectious Diseases (NIAID), finds that ...

The approval was based on results from a phase III trial that confirmed the bioequivalence of the biosimilar, formerly known as CT-P39, to omalizumab in patients with chronic spontaneous urticaria.

Robert Wood, the director of the Eudowood Division of Allergy, Immunology, and Rheumatology at Johns Hopkins Children’s Center, led a clinical trial on omalizumab—an already FDA-approved drug ...